Buscar
01/12/2025
ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
Grau-Pérez, M, Ciudad, C, Molina-Leyva, A, Martorell, A, Vilarrasa, E, Albert, I, Garcias-Ladaria, J, Melgosa, FJ, Rivera, R, Campos, M, Haselgruber, S, Ochando, G, Pascual, JC, García-Ruiz, R, Alfageme, F. ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa. DERMATOLOGY. 2025; 241(5-6)DOI:10.1159/000546647. PMID:40587963. IF:2.700(Q2/4D).
01/12/2025
REVIEW OF PATIENT DECISION AIDS FOR PSORIASIS
Ferrer, AL, Belinchón, I, Serra, MC, Clua, MG, Mate, AR, Suárez, BP, Alarcón, SS, de la Cueva, P. REVIEW OF PATIENT DECISION AIDS FOR PSORIASIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).
01/12/2025
UNDERSTANDING PATIENT PRIORITIES IN PSORIASIS TREATMENT: A REVIEW OF KEY DECISION-MAKING DRIVERS
Ferrer, AL, Belinchón, I, Serra, MC, Martínez, LE, Mate, AR, Suárez, BP, Alarcón, SS, de la Cueva, P. UNDERSTANDING PATIENT PRIORITIES IN PSORIASIS TREATMENT: A REVIEW OF KEY DECISION-MAKING DRIVERS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).
01/12/2025
HIGHER MORTALITY FOR GENERALIZED PUSTULAR PSORIASIS COMPARED WITH PLAQUE PSORIASIS HIGHLIGHTS THE NEED FOR IMPROVED TREATMENTS: INSIGHTS FROM A META-ANALYSIS
Strober, B, Puig, L, Lebwohl, MG, Lakshminarasimhan, B, Khan, SA, Pillai, N, Kappelhoff, B, Weatherill, A, Warren, RB. HIGHER MORTALITY FOR GENERALIZED PUSTULAR PSORIASIS COMPARED WITH PLAQUE PSORIASIS HIGHLIGHTS THE NEED FOR IMPROVED TREATMENTS: INSIGHTS FROM A META-ANALYSIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).
01/12/2025
Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group
Li, R, Hensley, PJ, Babjuk, M, Bukavina, L, Psutka, SP, Lerner, SP, O'Donnell, MA, Lotan, Y, Bree, KK, Redorta, JP, McConkey, DJ, Lee, BH, Mariappan, P, Mertens, LS, Soloway, MS, Svatek, RS, Tan, WS, Williams, SB, Gupta, S, Buckley, R, Kamat, AM. Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. European Urology Oncology. 2025; 8(6)DOI:10.1016/j.euo.2025.08.003. PMID:41076366. IF:9.300(Q1/1D).
01/12/2025
Twenty-year Patient-reported Outcomes After Surgery, Radiotherapy, or Brachytherapy for Localized Prostate Cancer
Zamora, V, Garin, O, Suárez, JF, Guedea, F, Pont, A, Pardo, Y, Goñi, A, Mariño, A, Hervás, A, Herruzo, I, Cabrera, P, Sancho, G, León, JPD, Macías, V, Gutiérrez, C, Castells, M, Ferrer, M. Twenty-year Patient-reported Outcomes After Surgery, Radiotherapy, or Brachytherapy for Localized Prostate Cancer. European Urology Open Science. 2025; 82DOI:10.1016/j.euros.2025.10.007. PMID:41311640. IF:4.500(Q1/2D).
01/12/2025
Platelet-rich plasma injections improve functional results over pulsed radiofrequency in ganglion impar treatments for coccydynia
Inga, JP, Sánchez, AF, Fragoso, JJV, Fa-Binefa, M, Molinas, IM. Platelet-rich plasma injections improve functional results over pulsed radiofrequency in ganglion impar treatments for coccydynia. Revista Espanola De Anestesiologia Y Reanimacion. 2025; 72(10)DOI:10.1016/j.redar.2025.501929. PMID:. IF:(Q/D).
01/12/2025
Persistent Critical Illness Across Borders: Are We Ready to Identify Them?
Kreling, GAD, Ranzani, O, Besen, BAMP. Persistent Critical Illness Across Borders: Are We Ready to Identify Them?. CRITICAL CARE MEDICINE. 2025; 53(12)DOI:10.1097/CCM.0000000000006868. PMID:41342860. IF:6.000(Q1/1D).